NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization499.66 mln
Float34.30 mln
Earnings Date11/18/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.03
Debt-free
ROE
-55.14
Deeply negative
ROA
-49.16
Deeply negative
Business Description
Artiva Biotherapeutics is a San Diego-based clinical-stage company, founded in 2019, that develops treatments using natural killer cells ? a type of immune cell the body uses to fight disease. Its main therapy, AlloNK, is a ready-to-use cell treatment being studied for a range of autoimmune conditions as well as certain blood cancers. The company is also advancing two additional cell-based treatments aimed at solid tumors, including breast, gastric, and bladder cancers, and at other blood-related cancers.